Factors affecting delivery of antiviral drugs to the brain
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Although the CNS is in part protected from peripheral insults by the blood-brain barrier and the blood-cerebrospinal fluid barrier, a number of human viruses gain access to the brain, replicate within this organ, or sustain latent infection. The efficacy of antiviral drugs towards the cerebral viral load is often limited as both blood-brain interfaces impede their cerebral distribution. For polar compounds, the major factor restricting their entry lies in the tight junctions that occlude the paracellular pathway across these barriers. For compounds with more favourable lipid solubility properties, CNS penetration will be function of a number of physicochemical factors that include the degree of lipophilicity, size and ability to bind to protein or red blood cells, as well as other factors inherent to the vascular and choroidal systems, such as the local cerebral blood flow and the surface area available for exchange. In addition, influx and efflux transport systems, or metabolic processes active in both capillary endothelial cells and choroid plexus epithelial cells, can greatly change the bioavailability of a drug in one or several compartments of the CNS. The relative importance of these various factors with respect to the CNS delivery of the different classes of antiviral drugs is illustrated and discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202607599 · Cited by 822 · cited 1×
“The pharmacological role of bcrp in the distribution of this drug has been studied in mice, either in the presence of a transporter inhibitor, or in bcrp knockout mice [120,121].”
Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study.
Butt, A. M., Jones, H. C., & Abbott, N. J. (1990) · The Journal of Physiology · doi:10.1113/jphysiol.1990.sp018243 · Cited by 775 · cited 1×
“cm2, [18]), and more importantly with respect to pharmacology, a very low paracellular permeability, virtually preventing the entry into the brain parenchyma of compounds which are not lipid soluble enough to dissolve into the cell membranes.”
Background
Cited by
Letendre, S. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.31 · Cited by 825
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497
Topological Polar Surface Area: A Useful Descriptor in 2D-QSAR
Prasanna, S., & Doerksen, R. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787002817 · Cited by 484
Strazielle, N., & Ghersi-Egea, J. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300518e · Cited by 263
Self-citationNanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting
Mahajan, H. S., Mahajan, M. S., Nerkar, P. P., & Agrawal, A. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838014 · Cited by 212
Choroid Plexus in Alzheimer’s Disease—The Current State of Knowledge
Gião, T., Teixeira, T., Almeida, M. R., & Cardoso, I. (2022) · Biomedicines · doi:10.3390/biomedicines10020224 · Cited by 64
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Metadata
- Authors
- Strazielle, N., & Ghersi-Egea, J.-F.
- Venue
- Reviews in Medical Virology
- Publisher
- Wiley
- Published
- 2005
- Volume
- 15
- Issue
- 2
- Pages
- 105-133
- ISSN
- 1052-9276 (ISSN-L)
- 1099-1654
- OpenAlex
- W1967221196
- Cited by
- 102
- References
- 2
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.